1267498-45-2

Basic information

• Product Name: methyl (7R)-14-cyclohexyl-7-{[2-(1,3-dioxo-1,3dihydro-2H-isoindol-2-yl)ethyl]amino}-7,8-dihydro-6H-indolo[1,2-e][1,5]benzoxazocine-11-carboxylate
• Synonyms: methyl (7R)-14-cyclohexyl-7-{[2-(1,3-dioxo-1,3dihydro-2H-isoindol-2-yl)ethyl]amino}-7,8-dihydro-6H-indolo[1,2-e][1,5]benzoxazocine-11-carboxylate
• CAS NO: 1267498-45-2
• Molecular Weight: 577.68
• Mol File: 1267498-45-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: methyl (7R)-14-cyclohexyl-7-{[2-(1,3-dioxo-1,3dihydro-2H-isoindol-2-yl)ethyl]amino}-7,8-dihydro-6H-indolo[1,2-e][1,5]benzoxazocine-11-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl (7R)-14-cyclohexyl-7-{[2-(1,3-dioxo-1,3dihydro-2H-isoindol-2-yl)ethyl]amino}-7,8-dihydro-6H-indolo[1,2-e][1,5]benzoxazocine-11-carboxylate(1267498-45-2)
• EPA Substance Registry System: methyl (7R)-14-cyclohexyl-7-{[2-(1,3-dioxo-1,3dihydro-2H-isoindol-2-yl)ethyl]amino}-7,8-dihydro-6H-indolo[1,2-e][1,5]benzoxazocine-11-carboxylate(1267498-45-2)

Safety Data

• Hazardous Substances Data: 1267498-45-2(Hazardous Substances Data)

Upstream product

• 78902-09-7 phthalimidoacetaldehyde diethyl acetal 
• 1267509-98-7 methyl (7R)-7-amino-14-cyclohexyl-7,8-dihydro-6H-indolo[1,2-e][1,5]benzoxazocine-11-carboxylate hydrochloride 
• 886041-63-0 methyl (7R)-7-azido-14-cyclohexyl-7,8-dihydro-6H-indolo-[1,2-e][1,5]benzoxazocine-11-carboxylate 
• 886041-54-9 methyl (7S)-14-cyclohexyl-7-hydroxy-7,8-dihydro-6H-indolo[1,2-e][1,5]benzoxazocine-11-carboxylate 
• 886041-53-8 3-cyclohexyl-2-{2-[(2S)-oxiran-2-ylmethoxy]phenyl}-1H-indole-6-carboxylic acid methyl ester 
• 863578-50-1 3-cyclohexyl-2-(2-hydroxy-phenyl)-1H-indole-6-carboxylic acid methyl ester 

Relevant articles and documents

Mitsunobu inversion of a secondary alcohol with diphenylphosphoryl azide. application to the enantioselective multikilogram synthesis of a HCV polymerase inhibitor

The development of a practical synthesis of the hepatitis C virus polymerase inhibitor 1 was necessary to support preclinical safety and human clinical studies. Significant challenges face the process chemist in developing a route to 1 that is amenable to